Folotyn for Non-Hodgkin's Lymphoma Monroe NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

Interlakes Oncology and Hematology PC
(315) 781-2250
675 W Washington St
Geneva, NY
Cichanowicz Cynthia Anp
(631) 204-9700
325 Meeting House Ln
Southampton, NY
Cancer Center At Glens Falls Hospital
(518) 926-6620
102 Park St
Glens Falls, NY
Avvento Louis MD
(631) 204-9700
325 Meeting House Ln
Southampton, NY
Avvento Louis MD
(631) 727-8500
1333 E Main St
Riverhead, NY
Orange County Radiation Oncology
(845) 534-4700
RR 9
Cornwall, NY
Vattigunta Sumithra
(716) 565-0355
45 Spindrift Dr
Buffalo, NY
White Plains Hospital Center Dickstein Cancer Treatment Center
(914) 681-2700

White Plains, NY
Cancer Center At Glens Falls Hospital
(518) 926-6670
102 Park St
Glens Falls, NY
Jaski John W MD
(518) 587-7670
31 Myrtle St
Saratoga Springs, NY

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Green Tea and Hematologic Malignancies Monroe NY
Read more about Green Tea May Lower the Risk of Hematologic Malignancies.
- Donor Stem-Cell Transplant for Acute Myeloid Leukemia Monroe NY